Download PDF

ERRATUM

The September 2013 issue of Conquering the Cancer Care Continuum, funded by Teva Pharmaceuticals, contained errors. In the article by Beth Faiman, PhD(c), MSN, APRN-BC, AOCN, titled “The Role of Biosimilars in Oncology: A Nurse’s Perspective,” the FDA approval language and indication for GRANIX™ (tbo-filgrastim) was incorrect, as was the package insert information cited in reference 7. Also, in the article by Steve Stricker, PharmD, MS, BCOP, titled “The Role of Biosimilars in Oncology: A Pharmacist’s Perspective,” Dr. Stricker mistakenly refers to tbo-filgrastim as a biosimilar. The correct approval language, indication, and reference are provided below.

GRANIX (tbo-filgrastim) was approved by the FDA on August 29, 2012, through a Biologics License Application and is therefore not a biosimilar as stated in the article.

GRANIX (tbo-filgrastim) is a leukocyte growth factor indicated for reduction in the duration of severe neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.

Reference 7 should be listed as follows: Granix [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc; 2013.

Teva Pharmaceuticals did not have any control or involvement in the content development of this newsletter.

We all go to our local pharmacy to get prescriptions filled for ourselves or a loved one. We usually notice, primarily based on the copayment, whether the prescription drug we are getting is a trade name we may see in a television commercial or it is a generic drug.
Cindy is a 52-year-old female with non-Hodgkin lymphoma. She plans to undergo an autologous hematopoietic stem cell transplant (HSCT). When discussing the risks associated with HSCT, the oncologist warns Cindy that her white blood cells (WBCs) will become critically low as a result of high-dose chemotherapy.
CJ is a 62-year-old female beginning chemotherapy with doxorubicin and cyclophosphamide for stage III breast cancer. To minimize the risk of neutropenia-associated complications, it is planned for CJ to return to the clinic daily following chemotherapy for injections of a colony-stimulating factor (CSF) until her absolute neutrophil count exceeds 10,000 × 106/L.
In April 2011, the National Comprehensive Cancer Network (NCCN) convened a summit of key stakeholders regarding the issues surrounding biosimilars in oncology care. The working group subsequently published a sentinel white paper outlining the regulatory, scientific, and patient safety issues surrounding the development and expansion of biosimilars in oncology care.

Results 1 - 4 of 4